Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011, 221:555-563.
Alvarez A., Opazo C., Alarcon R., Garrido J., Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997, 272:348-361.
Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002, 68:209-245.
Van der Zee E.A., Keijser J.N. Localization of pre- and postsynaptic cholinergic markers in rodent forebrain: a brief history and comparison of rat and mouse. Behav Brain Res 2011, 221:356-366.
Kadir A., Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J Nucl Med 2010, 51:1418-1430.
Bohnen N.I., Frey K.A. Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders. Mol Imaging Biol 2007, 9:243-257.
Namba H., Irie T., Fukushi K., Lyo M. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Res 1994, 667:278-282.
Kilbourn M.R., Snyder S.E., Sherman P.S., Kuhl D.E. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP). Synapse 1996, 22:123-131.
Darreh-Shori T., Kadir A., Almkvist O., Grut M., Wall A., Blomquist G., Eriksson B., Långström B., Nordberg A. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 2008, 29:168-184.
Haense C., Kalbe E., Herholz K., Hohmann C., Neumaier B., Krais R., Heiss W.-D. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging 2012, 33:867-877.
Herholz K. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008, 35(Suppl. 1):S25-S29.
Pappata S., Tavitian B., Traykov L., Jobert A., Dalger A., Mangin J.F., Crouzel C., Di Giamberardino L. In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 1996, 67:876-879.
Okamura N., Funaki Y., Tashiro M., Kato M., Ishikawa Y., Maruyama M., Ishikawa H., Meguro K., Iwata R., Yanai K. In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease. Br J Clin Pharmacol 2008, 65:472-479.
Shao X., Koeppe R.A., Butch E.R., Kilbourn M.R., Snyder S.E. Evaluation of 18F-labeled acetylcholinesterase substrates as PET radiotracers. Bioorg Med Chem 2005, 13:869-875.
Ryu E.K., Chen X. Development of Alzheimer's disease imaging agents for clinical studies. Front Biosci 2008, 13:777-789.
Lee S.-Y., Choe Y.S., Ryu E.K., Iimura Y., Choi Y., Lee K.-H., Kim B.-T. Is subnanomolar binding affinity required for the in vivo imaging of acetylcholinesterase? Studies on 18F-labeled G379. Nucl Med Biol 2006, 33:91-94.
Kikuchi T., Okamura T., Zhang M.-R., Fukushi K., Irie T. In vivo evaluation of N-[18F]fluoroethylpiperidin-4ylmethyl acetate in rats compared with MP4A as a probe for measuring cerebral acetylcholinesterase activity. Synapse 2010, 64:209-215.
Ronco C., Foucault R., Gillon E., Bohn P., Nachon F., Jean L., Renard P.-Y. New huprine derivatives functionalized at position 9 as highly potent acetylcholinesterase inhibitors. ChemMedChem 2011, 6:876-888.
Ronco C., Carletti E., Colletier J.-P., Weik M., Nachon F., Jean L., Renard P.-Y. Huprine derivatives as sub-nanomolar human acetylcholinesterase inhibitors: from rational design to validation by x-ray crystallography. ChemMedChem 2012, 7:400-405.
Camps P., Cusack B., Mallender W.D., El Achab R.E., Morral J., Muñoz-Torrero D., Rosenberry T.L. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol Pharmacol 2000, 57:409-417.
Laruelle M., Slifstein M., Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 2003, 5:363-375.
Aznavour N., Rbah L., Riad M., Reilhac A., Costes N., Descarries L., Zimmer L. A PET imaging study of 5-HT(1A) receptors in cat brain after acute and chronic fluoxetine treatment. Neuroimage 2006, 33:834-842.
Elsinga P.H., Hendrikse N.H., Bart J., Vaalburg W., van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 2004, 10:1493-1503.
Lacan G., Plenevaux A., Rubins D.J., Way B.M., Defraiteur C., Lemaire C., Aerts J., Luxen A., Cherry S.R., Melega W.P. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in the rat brain and peripheral tissues: microPET and ex vivo studies. Eur J Nucl Med 2008, 35:2256-2266.
Desai P.V., Raub T.J., Blanco M.J. How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg Med Chem Lett 2012, 22:6540-6548.
